Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform study of novel immunotherapy combinations versus pembrolizumab in previously untreated PD-L1-high advanced NSCLC
2021-005115-32Phase 2Active
- Sponsor
- GSK
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dostarlimab, belrestotug, GSK6097608B and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Objective response rate. Started Aug 2022; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-005115-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005115-32.